title: A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort.
abstract: OBJECTIVE
  To compare the incidence rates of malignancy among patients with psoriatic arthritis (PsA) and patients with rheumatoid arthritis (RA) in the Consortium of Rheumatology Researchers of North America (CORRONA) registry.
  
  
  METHODS
  We analyzed 2,970 patients with PsA (7,133 patient-years of followup) and 19,260 patients with RA (53,864 patient-years of followup). Using a standardized adjudication process, we identified 40 confirmed malignancies in the patients with PsA and 307 confirmed malignancies in those with RA. Incidence rates were calculated per 100 patient-years. Incidence rate ratios were estimated, with adjustment for age, sex, disease duration, body mass index, disease activity, year of enrollment, and medication use.
  
  
  RESULTS
  The overall malignancy incidence per 100 patient-years was similar between patients with PsA and patients with RA (0.56 [95% confidence interval (95% CI) 0.40-0.76] and 0.56 [95% CI 0.50-0.63], respectively). Nonmelanoma skin cancer was the most common type of cancer in the overall cohort, with an incidence rate of 0.21 (95% CI 0.12-0.35) in PsA, and 0.20 (95% CI 0.17-0.24) in RA, with a calculated incidence rate ratio of 1.05 (95% CI 0.61-1.80; P = 0.85). Lymphoma rates were similar in PsA and RA (0.04 [95% CI 0.01-0.12] and 0.04 [95% CI 0.02-0.06], respectively; incidence rate ratio 1.00 [95% CI 0.17-3.11]; P = 0.67). The adjusted incidence rate ratio of malignancy in PsA versus RA was 1.17 (95% CI 0.82-1.69; P = 0.37).
  
  
  CONCLUSIONS
  The incidence rates across malignancy subtypes were similar in the PsA and RA cohorts from a US registry.
authors.affiliation: Albert Einstein College of Medicine, Bronx, New York.
authors.forename: Rachael L
authors.initials: RL
authors.lastname: Gross
authors.forename: Julie S
authors.initials: JS
authors.lastname: Schwartzman-Morris
authors.forename: Michael
authors.initials: M
authors.lastname: Krathen
authors.forename: George
authors.initials: G
authors.lastname: Reed
authors.forename: Hong
authors.initials: H
authors.lastname: Chang
authors.forename: Katherine C
authors.initials: KC
authors.lastname: Saunders
authors.forename: Mark C
authors.initials: MC
authors.lastname: Fisher
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Greenberg
authors.forename: Chaim
authors.initials: C
authors.lastname: Putterman
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Mease
authors.forename: Alice B
authors.initials: AB
authors.lastname: Gottlieb
authors.forename: Joel M
authors.initials: JM
authors.lastname: Kremer
authors.forename: Anna
authors.initials: A
authors.lastname: Broder
mesh_terms: D000328:Adult; D000368:Aged; D015535:Arthritis, Psoriatic / Q000453:epidemiology*; D001172:Arthritis, Rheumatoid / Q000453:epidemiology*; D015331:Cohort Studies; D015897:Comorbidity; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008223:Lymphoma / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011446:Prospective Studies; D012042:Registries; D012878:Skin Neoplasms / Q000453:epidemiology*; D014481:United States / Q000453:epidemiology